<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="91">
  <stage>Registered</stage>
  <submitdate>1/08/2005</submitdate>
  <approvaldate>16/08/2005</approvaldate>
  <actrnumber>ACTRN12605000162617</actrnumber>
  <trial_identification>
    <studytitle>A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis</studytitle>
    <scientifictitle>A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin to determine the effect of dose on disease parameters in cystic fibrosis</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Human genetics and inherited disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A 6-month randomised double-blind trial of 250mg daily versus 1200mg weekly azithromycin in cystic fibrosis</interventions>
    <comparator />
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in FEV1 % predicted.</outcome>
      <timepoint>Measured at baseline, 1-month, 3-months, 6-months and 7-months (follow-up assessment)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Antibiotic use</outcome>
      <timepoint>All secondary outcomes will be measuredat baseline, 1-month, 3-months, 6-months and 7-months (follow-up assessment)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Hospital days</outcome>
      <timepoint>All secondary outcomes will be measuredat baseline, 1-month, 3-months, 6-months and 7-months (follow-up assessment).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>BMI,</outcome>
      <timepoint>All secondary outcomes will be measuredat baseline, 1-month, 3-months, 6-months and 7-months (follow-up assessment).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>QOL</outcome>
      <timepoint>All secondary outcomes will be measuredat baseline, 1-month, 3-months, 6-months and 7-months (follow-up assessment).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CRP levels</outcome>
      <timepoint>All secondary outcomes will be measuredat baseline, 1-month, 3-months, 6-months and 7-months (follow-up assessment).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cytokine response and bacteriology</outcome>
      <timepoint>All secondary outcomes will be measuredat baseline, 1-month, 3-months, 6-months and 7-months (follow-up assessment).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Consenting children and adults (age &gt;/6 years; weight &gt;/ 25kg) with Clinically stable (at least 2 weeks since last acute IV/oral antibiotic therapy; FEV1 within 10% of average for last 6 months). </inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Inability to provide written informed consent. Patients with a known allergy to macrolides. Patients taking terfenadine (Teldane), zidovudine (AZT), digoxin (Lanoxin), cyclosporin (Neroal). Patients taking any macrolide antibiotics in the 8 weeks prior to enrolment. Atypical mycobacteria infection of clinical significance. Commencement of anti-inflammatory therapy or mucolytic therapy in the month prior to enrolment, or during the duration of the study. Patient or their partner pregnant, or planning to become pregnant in the next 6 months. Patients with known liver impairment: portal hypertension or proven liver cirrhosis.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by Mater Pharmacy. Researchers, who were blinded to randomisation, were provided with a â¿¿randomisation scheduleâ¿. Stratified for gender and lung function each participant was allocated the next pharmacy study number from the randomisation schedule. Each pharmacy involved in study was provided with a randomisation code, where by each study number was allocated to either arm A or arm B of the trial. All labelling of A or B was removed from packaging prior to dispensing so that all participants received identical medication packages, regardless of treatment arm.</concealment>
    <sequence>Microsoft Excel was used by the Mater Pharmacy to generate the random allocation sequence. Randomisation is in blocks, stratified for gender and lung function.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>21/05/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>184</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Associate Professor Joseph McCormack, University of Queensland, Department of Medicine, Mater Hospital, South Brisbane, 4101</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Australian Cystic Fibrosis Research Trust</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pfizer Australia</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Queensland</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>n/a</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The University of Queensland</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Adults and Children's Hospitals</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Prince Charles Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Royal Children's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Gold Coast Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Assoc. Prof. Joseph McCormack</name>
      <address>Department of Medicine
University of Queensland
Level 1 Administration Building
Mater Adult Hospital
South Brisbane QLD 4101</address>
      <phone>+61 7 38408518</phone>
      <fax>+61 7 38401548</fax>
      <email>JMCCORMA@mater.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sharon Senini</name>
      <address>Department of Medicine
University of Queensland
Level 1 Administration Building
Mater Adult Hospital
South Brisbane QLD 4101</address>
      <phone>+61 7 38408916</phone>
      <fax>+61 7 38401548</fax>
      <email>sseeney@uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>